SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-408528"
 

Search: onr:"swepub:oai:DiVA.org:uu-408528" > Stepwise mass scree...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide : the STROKESTOP II study

Gudmundsdottir, Katrin Kemp (author)
Karolinska Institutet
Fredriksson, Tove (author)
Karolinska Institutet
Svennberg, Emma (author)
Karolinska Institutet
show more...
Al-Khalili, Faris (author)
Karolinska Institutet
Friberg, Leif (author)
Karolinska Inst, Danderyd Univ Hosp, Dept Clin Sci, Div Cardiovasc Med, SE-18288 Stockholm, Sweden
Frykman, Viveka (author)
Karolinska Institutet
Hijazi, Ziad (author)
Uppsala universitet,Kardiologi
Rosenqvist, Mårten (author)
Karolinska Inst, Danderyd Univ Hosp, Dept Clin Sci, Div Cardiovasc Med, SE-18288 Stockholm, Sweden
Engdahl, Johan (author)
Karolinska Institutet
show less...
 (creator_code:org_t)
2019-09-17
2020
English.
In: Europace. - : OXFORD UNIV PRESS. - 1099-5129 .- 1532-2092. ; 22:1, s. 24-32
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Aims: To study the prevalence of unknown atrial fibrillation (AF) in a high-risk, 75/76-year-old, population using N-terminal B-type natriuretic peptide (NT-proBNP) and handheld electrocardiogram (ECG) recordings in a stepwise screening procedure.Methods and results: The STROKESTOP II study is a population-based cohort study in which all 75/76-year-old in the Stockholm region (n = 28 712) were randomized 1:1 to be invited to an AF screening programme or to serve as the control group. Participants without known AF had NT-proBNP analysed and were stratified into low-risk (NT-proBNP <125 ng/L) and high-risk (NT-proBNP >= 125 ng/L) groups. The high-risk group was offered extended ECG-screening, whereas the low-risk group performed only one single-lead ECG recording. In total, 6868 individuals accepted the screening invitation of which 6315 (91.9%) did not have previously known AF. New AF was detected in 2.6% [95% confidence interval (CI) 2.2-3.0] of all participants without previous AF. In the high-risk group (n = 3766/6315, 59.6%), AF was diagnosed in 4.4% (95% CI 3.7-5.1) of the participants. Out of these, 18% had AF on their index-ECG. In the low-risk group, one participant was diagnosed with AF on index-ECG. The screening procedure resulted in an increase in known prevalence from 8.1% to 10.5% among participants. Oral anticoagulant treatment was initiated in 94.5% of the participants with newly diagnosed AF.Conclusion: N-terminal B-type natriuretic peptide-stratified systematic screening for AF identified 4.4% of the high-risk participants with new AF. Oral anticoagulant treatment initiation was well accepted in the group diagnosed with new AF.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Keyword

Atrial fibrillation
N-terminal B-type natriuretic peptide
Screening
Stroke
Oral anticoagulants

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

  • Europace (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view